Abstract
Aim:
To investigate the effect of breast cancer resistance protein (BCRP) inhibitors and pharmaceutical excipients on reducing the biliary excretion of camptothecins (CPT), ameliorating delayed-type diarrhea and intestinal mucosa damage induced by CPT.
Methods:
The cumulative biliary excretion of irinotecan (CPT-11) and hydroxycamptothecin (HCPT) with or without BCRP inhibitors and excipients was investigated in rats. The gastrointestinal toxicity, assessed as the diarrheal score, body weight change and microscopic pathological damage was also determined in rats.
Results:
Breast cancer resistance protein (BCRP) exhibited important effects on the biliary excretion of CPT. Coadministration of BCRP inhibitors such as GF120918 and cyclosporin A reduced the biliary excretion of CPT-11 and HCPT. Pharmaceutical excipients such as Pluronic F68 and PEG 2000 stearate also showed inhibitory effects on BCRP and similarly reduced CPT biliary excretion. The observed gastrointestinal toxicity was ameliorated by coadministration of BCRP inhibitors and excipients compared with injection of CPT-11 and HCPT alone.
Conclusion:
The use of excipients as inhibitors of BCRP is safe and relatively non-toxic, and may lead to important pharmacotherapeutic benefits by decreasing the gastrointestinal toxicity of CPT.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y . Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and for a relation toantitumour activity. Cancer Res 1989; 49: 1465–69.
Atsumi R, Suzuki W, Hakusui H . Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991; 21: 1159–69.
Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, et al. Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer. Chin J Cancer 2006; 8: 1035–8.
Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Mastui K, et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy of cisplatin. Jpn J Cancer Res 1995; 86: 406–13.
Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Mastui K, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164–8.
Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M, et al. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol Jpn 1995; 105: 447–60.
Creemers GJ, Lund B, Verweij J . Topoisomerase I inhibitors: topo-tecan and irinotecan. Cancer Treat Rev 1994; 20: 73–96.
Kaneda N, Yokokura T . Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 1990; 50: 1721–5.
Lokieo F, Canal P, Gay C, Chatelut E, Armand JP, Roche H, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, urine. Cancer Chemother Pharmacol 1995; 36: 79–82.
Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, Ratain MJ . Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723–5.
Takasuna K, Hagiwara T, Hirohashi M, Nomura M, Nagai E, Yokoiu T, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752–7.
Zhang L, Li S, Liao H, Jiang WQ, Guan ZZ . Phase I trial of pharmacokinetics and human tolerability to 10-hydroxycamptothecin in patients with advanced malignancy. Chin J Cancer 2001; 12: 1391–5.
Huang HQ, Jiang WQ, Hu XH, Lin XB, Liu KF, Li YH, et al. Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies. Chin J Cancer 2003; 12: 1334–8.
Horikawa M, Kato Y, Sugiyama Y Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 2002; 19: 1345–53.
Herwaarden AE, Schinkel AH . The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmcol Sci 2006; 27: 10–8.
Doyle LA, Ross DD . Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340–58.
Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2). J Cell Sci 2000; 113: 2011–21.
Kruijtzer CMF, Beijnen JH, Rosing H, Bokkel Huinink WW, Schot M, Jewell RC, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and p-glyco-protein inhibitor GF120918. J Clin Oncol 2002; 20: 2943–50.
Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651–6.
Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15649–54.
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T . In vitro and in vivo reversal of multidrug resistance by GF120918, an acrido-necarboxamide derivative. Cancer Res 1993; 53: 4595–602.
Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006; 58: 374–83.
Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 2007; 35: 1142–8.
Takasuma K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, et al. Optimal antidiarrhea treatmeat for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol 2006; 58: 494–503.
Hendricks CB, Rowinsky EK, Grochow LB . Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992; 52: 2268–78.
Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59: 5938–46.
Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y Effect of excipients on breast cancer resistance protein substrate uptake activity. J Controlled Release 2007; 124: 1–5.
Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV . Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion. Br J Cancer 2001; 85: 1987–97.
Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909–13.
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated nonsmall-cell lung cancer. J Clin Oncol 1992; 10: 16–20.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by the Knowledge Innovation Program of the Chinese Academy of Sciences (SIMM0709QN-10).
Rights and permissions
About this article
Cite this article
Zhang, Xx., Pan, Ws., Gan, L. et al. Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs. Acta Pharmacol Sin 29, 1391–1398 (2008). https://doi.org/10.1111/j.1745-7254.2008.00883.x
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00883.x
Keywords
This article is cited by
-
Structural dynamics of tween-based microemulsions for antimuscarinic drug mirabegron
Colloid and Polymer Science (2020)
